Treatment with somatostatin analogues and PRRT in metastatic middle ear adenoma with neuroendocrine features

by Joana Lima Ferreira, Bernardo Marques, C Willemien Menke-van der Houven van Oordt, Wouter W de Herder, Tessa Brabander, Johannes Hofland
Published 2021-05-01

Early 18F-FDG PET/CT Evaluation Shows Heterogeneous Metabolic Responses to Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer.

by Erik J van Helden, Otto S Hoekstra, Ronald Boellaard, Chantal Roth, Emma R Mulder, Henk M W Verheul, C Willemien Menke-van der Houven van Oordt
Published 2016-01-01

Potential and pitfalls of 89Zr-immuno-PET to assess target status: 89Zr-trastuzumab as an example

by Marc C. Huisman, C. Willemien Menke-van der Houven van Oordt, Josée M. Zijlstra, Otto S. Hoekstra, Ronald Boellaard, Guus A. M. S. van Dongen, Dhaval K. Shah, Yvonne W. S. Jauw
Published 2021-08-01

A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions...

by Agnes Jager, Elisabeth G. E. de Vries, C. Willemien Menke-van der Houven van Oordt, Patrick Neven, Clasina M. Venema, Andor W. J. M. Glaudemans, Yamei Wang, Rebecca G. Bagley, Maureen G. Conlan, Philippe Aftimos
Published 2020-09-01

Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody

by Yvonne W. S. Jauw, Marc C. Huisman, Tapan K. Nayak, Danielle J. Vugts, Randolph Christen, Valerie Meresse Naegelen, Dominik Ruettinger, Florian Heil, Adriaan A. Lammertsma, Henk M. W. Verheul, Otto S. Hoekstra, Guus A. M. S. van Dongen, C. Willemien Menke-van der Houven van Oordt
Published 2018-01-01

RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer

by Erik J. vanHelden, Lindsay Angus, C. Willemien Menke‐van der Houven van Oordt, Daniëlle A. M. Heideman, Eline Boon, Suzanne C. vanEs, Sandra A. Radema, Carla M. L. vanHerpen, Derk Jan A. deGroot, Elisabeth G. E. deVries, Maurice P. H. M. Jansen, Stefan Sleijfer, Henk M. W. Verheul
Published 2019-11-01

Visual and quantitative evaluation of [18F]FES and [18F]FDHT PET in patients with metastatic breast cancer: an interobserver variability study

by Lemonitsa H. Mammatas, Clasina M. Venema, Carolina P. Schröder, Henrica C. W. de Vet, Michel van Kruchten, Andor W. J. M. Glaudemans, Maqsood M. Yaqub, Henk M. W. Verheul, Epie Boven, Bert van der Vegt, Erik F. J. de Vries, Elisabeth G. E. de Vries, Otto S. Hoekstra, Geke A. P. Hospers, C. Willemien Menke-van der Houven van Oordt
Published 2020-04-01

Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-Like Receptor Ligand, as a Means of In Vivo Vaccination for Metastatic Pancreatic Duc...

by Bart Geboers, Florentine E. F. Timmer, Alette H. Ruarus, Johanna E. E. Pouw, Evelien A. C. Schouten, Joyce Bakker, Robbert S. Puijk, Sanne Nieuwenhuizen, Madelon Dijkstra, M. Petrousjka van den Tol, Jan J. J. de Vries, Daniela E. Oprea-Lager, C. Willemien Menke-van der Houven van Oordt, Hans J. van der Vliet, Johanna W. Wilmink, Hester J. Scheffer, Tanja D. de Gruijl, Martijn R. Meijerink, on behalf of the Dutch Pancreatic Cancer Group
Published 2021-08-01

Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study

by Anouk H. Eijkelboom, Linda de Munck, Marie-Jeanne T. F. D. Vrancken Peeters, Mireille J. M. Broeders, Luc J. A. Strobbe, Monique E. M. M. Bos, Marjanka K. Schmidt, Cristina Guerrero Paez, Marjolein L. Smidt, Maud Bessems, Janneke Verloop, Sabine Linn, Marc B. I. Lobbes, Aafke H. Honkoop, Desirée H. J. G. van den Bongard, Pieter J. Westenend, Jelle Wesseling, C. Willemien Menke-van der Houven van Oordt, Vivianne C. G. Tjan-Heijnen, Sabine Siesling, the NABON COVID-19 Consortium and the COVID and Cancer-NL Consortium
Published 2021-04-01